# 7th IMPAKT BREAST CANCER CONFERENCE
Brussels, Belgium, 7-9 May 2015

## Main Conference - Preliminary PROGRAMME - July

### Thursday, 7 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-12:00</td>
<td>Press Conference</td>
<td></td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Satellite Symposium 1</td>
<td></td>
</tr>
<tr>
<td>13:00-13:15</td>
<td>Official welcome</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Welcome to the IMPAKT Conference</td>
<td>Co-Founders</td>
</tr>
<tr>
<td>10’</td>
<td>Introduction to the IMPAKT Conference</td>
<td>Chairs</td>
</tr>
<tr>
<td>13:15-14:15</td>
<td>Opening Keynote session</td>
<td>Co-Chairs:</td>
</tr>
<tr>
<td>60’</td>
<td>To be defined</td>
<td></td>
</tr>
<tr>
<td>30’</td>
<td>Tracing the cellular origin of breast cancer</td>
<td>Cedric Blanpain, BE</td>
</tr>
<tr>
<td>20’</td>
<td>Clinical significance of the cellular origin of breast cancer Or Concepts on cells of origin of cancer: Implications for clinical practice</td>
<td>To be announced</td>
</tr>
<tr>
<td>10’</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>14:15-15:45</td>
<td>Session 1</td>
<td>Co-Chairs:</td>
</tr>
<tr>
<td>90’</td>
<td>The molecular origin of breast cancer: Clinical significance of genomic patterns</td>
<td>To be defined</td>
</tr>
<tr>
<td>20’</td>
<td>Genomic ventures to explore tumour progression and intra-tumour heterogeneity in breast cancer</td>
<td>Peter van Loo, UK</td>
</tr>
<tr>
<td>20’</td>
<td>APOBEC and mutation signatures: Connecting immune response and breast cancer development or APOBEC mutation signatures and the origin of breast cancer</td>
<td>To be announced</td>
</tr>
<tr>
<td>15’</td>
<td>Which mutations are relevant? Strategies for identification</td>
<td>To be announced</td>
</tr>
<tr>
<td>15’</td>
<td>Therapeutic implications of mutational evolution in breast cancer</td>
<td>Lajos Pusztai, US</td>
</tr>
<tr>
<td>20’</td>
<td>Q&amp;A / General Discussion</td>
<td></td>
</tr>
<tr>
<td>15:45-16:15</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:15-17:45</td>
<td>Best abstracts session – Oral abstracts</td>
<td>Co-Chairs:</td>
</tr>
<tr>
<td>90’</td>
<td>6 x abstracts@10mins, 2 x Discussants@15’ each incl. Q&amp;A</td>
<td>Nick Turner, UK and Carsten Denkert, DE</td>
</tr>
<tr>
<td>10’</td>
<td>Abstract 1</td>
<td></td>
</tr>
<tr>
<td>10’</td>
<td>Abstract 2</td>
<td></td>
</tr>
<tr>
<td>10’</td>
<td>Abstract 3</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Discussant Abstracts 1-3</td>
<td></td>
</tr>
<tr>
<td>10’</td>
<td>Abstract 4</td>
<td></td>
</tr>
<tr>
<td>10’</td>
<td>Abstract 5</td>
<td></td>
</tr>
<tr>
<td>10’</td>
<td>Abstract 6</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Discussant Abstracts 4-6</td>
<td></td>
</tr>
<tr>
<td>17:45-19:00</td>
<td>Welcome reception and Poster Walk</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session/Panel</td>
<td>Details</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 08:30-09:15 | Keynote lecture | Co-Chairs: To be defined  
30’ Dissecting the proteome of breast cancer  
15’ Q&A |
| 09:15-10:15 | Session 2 Mutations and therapy resistance: Impact of mutations in the clinic | Co-Chairs: To be defined  
15’ ESR1 mutations and resistance to endocrine therapy  
15’ PIK3CA + HER2 mutations  
15’ Clinical relevance: How do we manage mutational mechanisms of resistance?  
15’ Q&A / General Discussion |
| 10:15-10:45 | Coffee break | |
| 10:45-12:15 | Session 3 Microenvironment and metastatic cascade in breast cancer | Co-Chairs: To be defined  
20’ Tumour evolution in the metastatic setting  
20’ The impact of tumour genetics on host immune response  
20’ Strategies to modulate the immune system in breast cancer: Checkpoint inhibitors and beyond  
15’ Clinical perspectives  
15’ Q&A / General Discussion |
| 12:15-13:15 | Satellite Symposium 2 | |
| 13:15-13:45 | Lunch | |
| 13:45-15:15 | Satellite Symposium 3 | |
| 15:15-15:30 | Coffee Break | |
| 15:30-17:35 | Session 4 Translational clinical trial approaches in early stage breast cancer | Co-Chairs: To be defined  
20’ New aspects of molecular imaging in breast cancer  
20’ If I would start the I-SPY trials again what would I do differently?  
20’ Selection criteria for post neoadjuvant therapy concepts  
20’ POETIC strategies: Optimising neo-adjuvant and window studies in oestrogen receptor positive breast cancer  
45’ Panel discussion: Integration of neoadjuvant and adjuvant trials – do we need new strategies for early breast cancer? |
| 17:35-18.35 | Keynote Lecture 3 | Co-Chairs: To be defined  
30’ The impact of germline genetics on breast cancer risk and integration in clinical practice  
20’ Clinical interpretation  
10’ Q&A / General Discussion |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
<th>Co-Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:00</td>
<td>Session 5 – Debate</td>
<td>Chemotherapy will have a trivial role in the future of precision medicine</td>
<td>Co-Chairs: To be defined</td>
</tr>
<tr>
<td>20’</td>
<td>Speaker Pro</td>
<td>David Cameron, UK</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Speaker Contra</td>
<td>Larry Norton, US</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Moderated discussion with audience</td>
<td>Lead by Fabrice André, FR</td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-10:45</td>
<td>Susan G. Komen for the Cure® award session</td>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td>10:45-11:45</td>
<td>Session 6</td>
<td>Triple negative breast cancer: First results from tackling the diversity</td>
<td>Co-Chairs: To be defined</td>
</tr>
<tr>
<td>15’</td>
<td>Genomic and morphological heterogeneity in TNBC</td>
<td>Jorge Reis-Filho, US</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Platinum and targeted therapy in TN breast cancer- for all patients or only a subset?</td>
<td>Andrew Tutt, UK</td>
<td></td>
</tr>
<tr>
<td>30’</td>
<td>Panel discussion: Potential resistance targets, recent study results and new trial concepts</td>
<td>Panellists: Jorge Reis-Filho, US Andrew Tutt, UK Nick Turner, UK + 2-4 among the invited speakers</td>
<td></td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Closing remarks</td>
<td></td>
<td>Co-Chairs: Nick Turner, UK and Carsten Denkert, DE</td>
</tr>
</tbody>
</table>